Huma, formerly Medopad, is a global digital health technology company that advances digital-first care delivery and research to help people live longer, fuller lives.
Huma's mission to help people with chronic, complex, and rare diseases to live longer, better lives.
Huma was founded in 2011 by Dan Vahdat and Rich Khatib. The company is headquartered in London, UK, with offices in New York, Shanghai and Hamburg.
Huma’s software lets clinicians monitor patients remotely through a mobile app. It also uses a range of wearables and other devices to gather data on things like heart rate and oxygen saturation.
Huma's platform has been shown to almost double clinical capacity, reduce readmissions by over a third, enable better diversity, participant retention and protocol adherence, whilst allowing trials to run within weeks.
Huma's award-winning modular platforms are used by more than 3,000 hospitals and clinics, with 1.8 million active users. The company forged a new partnership with AstraZeneca to scale innovation for digital health.
Huma is backed by Leaps by Bayer, Hitachi Ventures, AstraZeneca, NWS Holding, Healthbox, Bupa, Sony Innovation Fund, Unilever Ventures, Samsung NEXT, and others. The company raised £25M ($33M) in new financing on Mar 23, 2022. This brings Huma's total funding to $217M to date.